Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Richmond, Virginia 23284


This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Study summary:

The objectives of this study are: 1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV). 2. To evaluate the safety and tolerability of AA administered intravenously.


Inclusion Criteria: - Is between the ages of 18 and 45 years, inclusive. - Has a body mass index (BMI) between 18 and 32 kg/m2. - Of sound health and has the ability to understand the requirements of the study and is willing to comply with all study requirements and procedures. Exclusion Criteria: - Participates in activities that would not allow accurate evaluation of the pharmacokinetics of Ascorbic Acid - Medical or physical conditions that would not allow safe participation and/or accurate evaluation of the pharmacokinetics of Ascorbic Acid - Has participated in an investigational drug study within the 30 days prior to CRU admission.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

A Pharmacokinetics Study of Intravenous Ascorbic Acid

Official Title:

A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

45 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

McGuff Pharmaceuticals, Inc.

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Endpoint Classification: Pharmacokinetics Study, I

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Damon P Jones, BS/MBA
Study Director
McGuff Pharmaceuticals, Inc.

Study Dates

Start Date:September 2015
Completion Date:January 2016
Completion Type:Actual
Primary Completion Date:November 2015
Primary Completion Type:Actual
Verification Date:March 2016
Last Changed Date:March 22, 2016
First Received Date:August 24, 2015

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Changes from pre-dose physical exam findings to discharge
Time Frame:1 day
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Changes from Baseline in clinical laboratory and vital signs to discharge
Time Frame:1 day
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system
Time Frame:1 day
Safety Issues:True
Outcome Type:Primary Outcome
Measure:Concentration of Ascorbic Acid (µM) in plasma
Time Frame:1 day
Safety Issues:False

Study Interventions

Intervention Type:Drug
Name:Ascor L 500® (Ascorbic Acid Injection, USP)
Description:A sterile, solution containing 500 mg ascorbic acid per mL
Arm Name:Single Group
Other Name:Ascorbic Acid

Study Arms

Study Arm Type:Experimental
Arm Name:Single Group

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:McGuff Pharmaceuticals, Inc.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.